
Colorectal cancer surveillance in the community
Early-stage colorectal cancer (CRC) patients are recommended to get a review every 3-6 months for 5 years after operation for the detection of cancer recurrence. As an increasing number of

Early-stage colorectal cancer (CRC) patients are recommended to get a review every 3-6 months for 5 years after operation for the detection of cancer recurrence. As an increasing number of

Non-Hodgkin’s lymphoma is a common form of blood cancer with a high proportion of patients either developing treatment resistance or relapsing after initial treatment. The combination of multiple therapies is

Hepatocellular carcinoma (HCC) remains difficult to treat due to a lack of effective treatment options. While various drugs have shown promising preclinical results, poor drug combination design results in less

Primary Epstein-Barr virus (EBV)-positive nodal T/NK-cell lymphoma (PTCL-EBV) is an aggressive and poorly understood disease that occurs mostly in East Asia. In this collaborative study, led by A/Prof Ng Siok

Adult T-cell leukemia/lymphoma (ATL) is a genetically complex form of blood cancer. In this study led by A/Prof Takaomi Sanda, the authors investigated the roles, functions as well as factors

The leakage of chemotherapeutic drugs into tissues other than the tumour can result in adverse side effects. Efforts have been made to devise novel drug delivery methods to improve drug

Platinum resistance is a major contributor to ovarian cancer mortality and presents a considerable clinical challenge, necessitating the development of better treatments for platinum-resistant patients. In this editorial, A/Prof. David

Aberrant activation of the transcription factor, STAT3, can promote cancer progression and occurs in various cancer types including breast, prostate, pancreas, liver, brain and leukemia. This study, co-led by A/Prof

Black cardamom (A. subulatum), a commonly used spice, is also used in traditional medicine as a component of ayurvedic formulations for the treatment of lung conditions. In this article co-authored

The drug Selinexor blocks specific protein that has been shown to be overexpressed in many types of cancer. Authors in this study evaluated the tolerability and the safety of this